+

WO2007103288A3 - Engineered antibody drug conjugates - Google Patents

Engineered antibody drug conjugates Download PDF

Info

Publication number
WO2007103288A3
WO2007103288A3 PCT/US2007/005552 US2007005552W WO2007103288A3 WO 2007103288 A3 WO2007103288 A3 WO 2007103288A3 US 2007005552 W US2007005552 W US 2007005552W WO 2007103288 A3 WO2007103288 A3 WO 2007103288A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug conjugates
antibody drug
engineered antibody
ligand drug
drugs
Prior art date
Application number
PCT/US2007/005552
Other languages
French (fr)
Other versions
WO2007103288A2 (en
Inventor
Charlotte Mcdonagh
Paul Carter
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of WO2007103288A2 publication Critical patent/WO2007103288A2/en
Publication of WO2007103288A3 publication Critical patent/WO2007103288A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides ligand drug conjugates for targeted delivery of drugs. The ligand drug conjugates have potent cytotoxic activity against antigen-specific targets, as compared with intact antibody drug conjugates.
PCT/US2007/005552 2006-03-02 2007-03-02 Engineered antibody drug conjugates WO2007103288A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77847206P 2006-03-02 2006-03-02
US60/778,472 2006-03-02
US87234806P 2006-12-01 2006-12-01
US60/872,348 2006-12-01

Publications (2)

Publication Number Publication Date
WO2007103288A2 WO2007103288A2 (en) 2007-09-13
WO2007103288A3 true WO2007103288A3 (en) 2007-11-29

Family

ID=38475456

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/005552 WO2007103288A2 (en) 2006-03-02 2007-03-02 Engineered antibody drug conjugates

Country Status (1)

Country Link
WO (1) WO2007103288A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023356B2 (en) 2007-03-15 2015-05-05 Ludwig Institute For Cancer Research Ltd Treatment method using EGFR antibodies and SRC inhibitors and related formulations
US11844839B2 (en) 2016-03-25 2023-12-19 Seagen Inc. Process for the preparation of pegylated drug-linkers and intermediates thereof
JP7458997B2 (en) 2018-05-29 2024-04-01 ブリストル－マイヤーズ スクイブ カンパニー Modified self-cleaving moieties for use in prodrugs and conjugates and methods of use and preparation thereof

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2335728A1 (en) 2001-05-11 2011-06-22 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
JP5532486B2 (en) 2007-08-14 2014-06-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Monoclonal antibody 175 targeting EGF receptor and derivatives and uses thereof
HUE031533T2 (en) 2007-10-19 2017-07-28 Seattle Genetics Inc Cd19 binding agents and uses thereof
WO2009059309A2 (en) * 2007-11-01 2009-05-07 Panacea Pharmaceuticals, Inc. Furin-cleavable peptide linkers for drug-ligand conjugates
PL2310412T3 (en) 2008-06-20 2018-10-31 Novartis Ag Immunoglobulins with reduced aggregation
EP2310970B1 (en) 2008-06-20 2013-05-29 Novartis AG Methods to identify macromolecule binding and aggregation prone regions in proteins and uses therefor
PL2326350T3 (en) 2008-09-08 2014-03-31 Psma Dev Company L L C Compounds for killing psma-expressing, taxane-resistant cancer cells
CA2763935A1 (en) * 2009-06-04 2010-12-09 Novartis Ag Methods for identification of sites for igg conjugation
EP2480230A4 (en) * 2009-09-24 2015-06-10 Seattle Genetics Inc LIGAND-DRUG CONJUGATES DR5
DK2646470T3 (en) 2010-11-30 2017-05-08 Hoffmann La Roche ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH LOW AFFINITY AND ITS USE FOR TRANSPORTING THERAPEUTIC SCFV OVER THE BLOOD-BRAIN BARRIER
BR112013031819B1 (en) 2011-06-10 2022-05-03 Mersana Therapeutics, Inc Polymeric support, pharmaceutical composition, compound and support use
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
US10431325B2 (en) 2012-08-03 2019-10-01 Novartis Ag Methods to identify amino acid residues involved in macromolecular binding and uses therefor
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
MX379355B (en) 2012-12-21 2025-03-11 Altrubio Inc HYDROPHILIC SELF-DESTRUCTIVE LINKETS AND CONJUGATES THEREOF.
CN110143999B (en) 2013-03-15 2023-12-05 酵活英属哥伦比亚省公司 Cytotoxic and antimitotic compounds and methods of use thereof
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
ES2726850T3 (en) 2013-10-11 2019-10-09 Mersana Therapeutics Inc Protein-polymer-drug conjugates
PL3054992T3 (en) 2013-10-11 2020-01-31 Asana Biosciences, Llc Protein-polymer-drug conjugates
CN105764503A (en) 2013-10-15 2016-07-13 西雅图基因公司 PEGylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
BR112016012538A2 (en) 2013-12-17 2017-09-26 Novartis Ag cytotoxic peptides and conjugates thereof
MX2016008355A (en) * 2013-12-23 2016-10-28 Zymeworks Inc Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof.
CA2935077C (en) 2013-12-27 2022-03-15 Geoffrey C. Winters Sulfonamide-containing linkage systems for drug conjugates
EP3100731A4 (en) * 2014-01-29 2017-12-20 Shanghai Hengrui Pharmaceutical Co., Ltd. Ligand-cytotoxicity drug conjugate, preparation method therefor, and uses thereof
JP6681346B2 (en) 2014-06-13 2020-04-15 ノバルティス アーゲー Auristatin derivative and its conjugate
CN106661124A (en) 2014-06-20 2017-05-10 荷商台医(有限合伙)公司 Anti-folate receptor aplha (FRA) antibody-drug conjugates and methods of using thereof
AR100919A1 (en) * 2014-06-20 2016-11-09 Bioalliance Cv ANTI-CD22 DRUG-ANTIBODY CONJUGATES AND SAME USE METHODS
HRP20220123T1 (en) 2014-09-17 2022-04-15 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
NZ743815A (en) 2016-01-08 2023-06-30 Altrubio Inc Tetravalent anti-psgl-1 antibodies and uses thereof
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
KR102493853B1 (en) * 2016-08-19 2023-01-30 브리스톨-마이어스 스큅 컴퍼니 Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of manufacture and use
US20180118811A1 (en) 2016-10-19 2018-05-03 Invenra Inc. Antibody constructs
JP2020506716A (en) 2016-12-22 2020-03-05 ウニヴェルシタ・デリ・ストゥディ・マニャ・グレチア・カタンツァーロ Monoclonal antibodies targeting unique sialoglycosylated cancer-related epitopes on CD43
AU2018237683A1 (en) 2017-03-24 2019-10-31 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CN113227127A (en) 2018-06-05 2021-08-06 伦敦大学国王学院 Delivering payload to gastrointestinal System BTNL3/8 targeting construct
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006446A2 (en) * 1997-07-30 1999-02-11 Fuchsbauer Hans Lothar Method for transglutaminase-catalyzed coupling of protein or peptide to a support
US20040052793A1 (en) * 2001-02-22 2004-03-18 Carter Paul J. Caspase activivated prodrugs therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006446A2 (en) * 1997-07-30 1999-02-11 Fuchsbauer Hans Lothar Method for transglutaminase-catalyzed coupling of protein or peptide to a support
US20040052793A1 (en) * 2001-02-22 2004-03-18 Carter Paul J. Caspase activivated prodrugs therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUTHERLAND ET AL.: "Lysosomal Trafficking Cysteine Protease Metabolism Confer Targe-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, no. 15, 16 February 2006 (2006-02-16), pages 10540 - 10547, XP055009569, DOI: doi:10.1074/jbc.M510026200 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023356B2 (en) 2007-03-15 2015-05-05 Ludwig Institute For Cancer Research Ltd Treatment method using EGFR antibodies and SRC inhibitors and related formulations
US11844839B2 (en) 2016-03-25 2023-12-19 Seagen Inc. Process for the preparation of pegylated drug-linkers and intermediates thereof
JP7458997B2 (en) 2018-05-29 2024-04-01 ブリストル－マイヤーズ スクイブ カンパニー Modified self-cleaving moieties for use in prodrugs and conjugates and methods of use and preparation thereof

Also Published As

Publication number Publication date
WO2007103288A2 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
WO2007103288A3 (en) Engineered antibody drug conjugates
WO2007137170A3 (en) Anti-glypican-3 antibody drug conjugates
WO2008112873A3 (en) Binding ligand linked drug delivery conjugates of tubulysins
HK1190909A1 (en) Drug delivery methods, structures, and compositions for nasolacrimal system
WO2011057225A3 (en) Self-assembled particles from zwitterionic polymers and related methods
WO2007130491A3 (en) Patient customized therapeutic regimens
HRP20130547T1 (en) Conjugates for targeted drug delivery across the blood-brain barrier
WO2006060547A3 (en) Systems and methods for intra-oral drug delivery
WO2007105027A8 (en) Anticancer drugs conjugated to antibody via an enzyme cleavable linker
IL231321A0 (en) Intraocular drug delivery systems
WO2009137378A3 (en) Sequential administration of chemotherapeutic agents for treatment of cancer
WO2008120207A3 (en) Compositions for nasal delivery
WO2013072813A3 (en) Cytotoxic peptides and antibody drug conjugates thereof
WO2007112193A3 (en) Camptothecin-binding moiety conjugates
WO2008112288A3 (en) Oligomer-opioid agonist conjugates
EP1998751A4 (en) Devices, systems and methods for medicament delivery
WO2007106744A3 (en) Anti-5t4 antibodies and uses thereof
WO2009100194A3 (en) Camptothecin-binding moiety conjugates
WO2009121039A3 (en) Administration of benzodiazepine compositions
WO2009087634A3 (en) Methods and compositions for oral administration of insulin
LTPA2019508I1 (en) Drug delivery system for the delivery of hard-water-soluble, pharmaceutically active substances
WO2009042064A3 (en) Oligomer-nucleoside phosphate conjugates
WO2009005718A8 (en) Polypeptide microparticles having sustained release characteristics, methods and uses
MX2010005813A (en) Oligomer-tricyclic conjugates.
EA200900958A1 (en) DRUG NEVIRAPIN PREPARATION

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07752266

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07752266

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载